Advertisement
Advertisement
NEUP
Neuphoria Therapeutics Inc. Common Stock
3.86
USDSponsored
+0.04
+1.05%
Aug 10, 16:00 UTC -4
Closed
After-Market
3.81
-0.05
-1.30%
NEUP Earnings Reports
Positive Surprise Ratio
NEUP beat 2 of 4 last estimates.
50%
Next Report
Date of Next Report
Sep 28, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.57
Implied change from Q3 26 (Revenue/ EPS)
--
/+533.33%
Implied change from Q4 25 (Revenue/ EPS)
-100.00%
/-90.16%
Neuphoria Therapeutics Inc. Common Stock earnings per share and revenue
On May 15, 2026, NEUP reported earnings of -0.09 USD per share (EPS) for Q3 26, beating the estimate of -0.98 USD, resulting in a 90.90% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.07% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 5 analysts forecast an EPS of -0.57 USD, with revenue projected to reach -- USD, implying an increase of 533.33% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were Neuphoria Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Neuphoria Therapeutics Inc. Common Stock reported EPS of -$0.09, beating estimates by 90.9%, and revenue of $0.00, 0% as expectations.
How did the market react to Neuphoria Therapeutics Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -7.07%, changed from $5.09 before the earnings release to $4.73 the day after.
When is Neuphoria Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Sep 28, 2026.
What are the forecasts for Neuphoria Therapeutics Inc. Common Stock's next earnings report?
Based on 5
analysts, Neuphoria Therapeutics Inc. Common Stock is expected to report EPS of -$0.57 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement